Screening compound: C26H30F2N2O2 (C076-0427)

Screening compound: C<sub>26</sub>H<sub>30</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> (C076-0427)
Screening compound: C<sub>26</sub>H<sub>30</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> (C076-0427) alternative view

Chemical Structure Depiction of ChemDiv screening compound
C26H30F2N2O2 (C076-0427)

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

C076-0427

Molecular Formula

C26H30F2N2O2 (C26 H30 F2 N2 O2)

Compound Name

4-(4-butylcyclohexanecarbonyl)-7-fluoro-5-(4-fluorophenyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-one

IUPAC name

4-(4-butylcyclohexanecarbonyl)-7-fluoro-5-(4-fluorophenyl)-2345-tetrahydro-1H-14-benzodiazepin-2-one

SMILES

CCCCC(CC1)CCC1C(N(C1)C(c(cc2)ccc2F)c(cc(cc2)F)c2NC1=O)=O

InChI

InChI=1S/C26H30F2N2O2/c1-2-3-4-17-5-7-19(8-6-17)26(32)30-16-24(31)29-23-14-13-21(28)15-22(23)25(30)18-9-11-20(27)12-10-18/h9-15,17,19,25H,2-8,16H2,1H3,(H,29,31)/t17?,19?,25-/m0/s1

InChI Key

NAEPYRHHQRJPOV-HGEUABKPSA-N

MDL Number (MFCD)

MFCD04455412

C26H30F2N2O2 (C076-0427) in Drug Discovery

Included in Screening Libraries

3D-Biodiversity Library (27607 compounds)

Allosteric Kinases Inhibitors Library (23117 compounds)

Human Kinases Annotated Library (2415 compounds)

Human Transcription Factors Annotated Library (5098 compounds)

KRAS-Targeted Library (16000 compounds)

Macl-GPIb alpha Interaction Library (22969 compounds)

Protein-Protein Interaction Library (218420 compounds)

ChemoGenomic Annotated Library for Phenotypic Screening (89798 compounds)

Epigenetics Focused Set (26518 compounds)

MCE-18 Trends in Medicinal Chemistry (51288 compounds)

Recognition Elements PPI Library (24135 compounds)

Target Identification, Phenotypic Screening library (TIPS) (27612 compounds)

Included in 1.7M Stock Database

Structure:
  • 3D
  • Mimetics
Therapeutical areas:
  • Cancer
  • Female
  • Congenital
  • Skin
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Hemic and lymphatic
  • Cardiovascular
Targets:
  • Kinases
  • Kinases
Mechanism of action:
  • PPI modulators
  • PPI modulators

References: we are preparing a list of scientific research reports with C26H30F2N2O2 (C076-0427) chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound C26H30F2N2O2 (C076-0427)?
Check Price and Availability of C26H30F2N2O2 (C076-0427), then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of C26H30F2N2O2 (C076-0427) you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for C26H30F2N2O2 (C076-0427)
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for C26H30F2N2O2 (C076-0427)
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of C26H30F2N2O2 (C076-0427) available by request